To be or not to be - Obese

Endocrinology

Volumn 152, Issue 10, 2011, Pages 3592-3596

  Maudsley, Stuart ^a   Martin, Bronwen ^a   Egan, Josephine M ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEPRAMONE; EXENDIN 4; FLUOXETINE; INSULIN; LIRAGLUTIDE; METFORMIN; NALOXONE; NORBINALTORPHIMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHENTERMINE; PLACEBO; PRAMLINTIDE; RIMONABANT; SIBUTRAMINE; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN;

AGITATION; ANXIETY; BARIATRIC SURGERY; BODY MASS; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; DEPRESSION; DISEASE ASSOCIATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; FOOD INTAKE; HEART PALPITATION; HUMAN; INSOMNIA; IRRITABILITY; LIFESTYLE MODIFICATION; NERVOUSNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; SHORT SURVEY; SIDE EFFECT; SUICIDAL BEHAVIOR;

AFFECT; ANIMALS; BODY WEIGHT; BRAIN; MALE; RECEPTOR, CANNABINOID, CB1; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION;

EID: 80053161226     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-1615     Document Type: Short Survey

References (42)

1. Flegal KM, Carroll MD, Ogden CL, Curtin LR 2010 Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303:235-241
2. Lockie SH, Czyzyk TA, Chaudhary N, Perez-Tilve D, Woods SC, Oldfield BJ, Statnick MA, Tschoep M 2011 CNS opioid signaling separates cannabinoid receptor 1 mediated effects on body weight and mood-related behavior in mice. Endocrinology 152:3661-3667
3. Haslam DW, James WP 2005 Obesity. Lancet 366:1197-1209 (Pubitemid 41393598)
4. Scarborough P, Bhatnagar P, Wickramasinghe KK, Allender S, Foster C, RaynerM11May2011 The economic burden of ill health due to diet, physical inactivity, smoking, alcohol and obesity in the UK: an update to 2006-07 NHS costs. J Public Health (Oxf) 10.1093/ pubmed/fdr033
5. Bittman M 2011 Bad food? Tax it, and subsidize vegetables. New York Times, July 23, 2011; 1-7
6. Hussain SS, Bloom SR 2011 The pharmacological treatment and management of obesity. Postgrad Med 123:34-44
7. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV 1997 Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337:581-588 (Pubitemid 27360757)
8. Nisoli E, Carruba MO 2003 A benefit-risk assessment of sibutramine in the management of obesity. Drug Saf 26:1027-1048 (Pubitemid 37452644)
9. Cercato C, Roizenblatt VA, Leança CC, Segal A, Lopes Filho AP, Mancini MC, HalpernA2009Arandomized double-blind placebocontrolled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects. Int J Obes 33:857-865
10. Wise SD 1992 Clinical studies with fluoxetine in obesity. Am J Clin Nutr 55:181S-184S
11. Spiegelman BM, Flier JS 2001 Obesity and the regulation of energy balance. Cell 104:531-543 (Pubitemid 32201948)
12. Di Marzo V, BifulcoM,De Petrocellis L 2004 The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3:771-784 (Pubitemid 39242829)
13. Kim W, Doyle ME, Liu Z, Lao Q, Shin YK, Carlson OD, Kim HS, Thomas S, Napora JK, Lee EK, Moaddel R, Wang Y, Maudsley S, Martin B, KulkarniRN, EganJM2011 Cannabinoids inhibit insulin receptor signaling in pancreatic β-cells. Diabetes 60:1198-1209
14. Butler H, Korbonits M 2009 Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists. Eur J Endocrinol 161:655-662
15. Di Marzo V, Matias I 2005 Endocannabinoid control of food intake and energy balance. Nat Neurosci 8:585-589 (Pubitemid 40594198)
16. Rinaldi-Carmona M, Barth F, Héaulme M, Alonso R, Shire D, Congy C, Soubrié P, Brelière JC, Le Fur G 1995 Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 56: 1941-1947
17. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA 2003 Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology 167:103-111 (Pubitemid 36535298)
18. HerlingAW,Kilp S, Elvert R, Haschke G, KramerW2008 Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed Wistar rats. Endocrinology 149:2557-2566 (Pubitemid 351574492)
19. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF RIODiabetes Study Group 2006 Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 368:1660-1672 (Pubitemid 46048528)
20. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S RIOEurope Study Group 2005 Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIOEurope study. Lancet 365:1389-1397 (Pubitemid 40523733)
21. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group 2006 Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295:761-775 (Pubitemid 43244304)
22. Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group 2005 Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121-2134
23. Di Marzo V, Després JP 2009 CB1 antagonists for obesity-what lessons have we learned from rimonabant? Nat Rev Endocrinol 5:633-638
24. Li M, Cheung BM 2009 Pharmacotherapy for obesity. Br J Clin Pharmacol 68:804-810
25. Tindle HA, Omalu B, Courcoulas A, Marcus M, Hammers J, Kuller LH 2010 Risk of suicide after long-term follow-up from bariatric surgery. Am J Med 123:1036-1042
26. Rahman S 2010 Targeting opioid receptors: a new treatment for brain disorders. CNS Neurol Disord Drug Targets 9:128
27. Herman BH, Holtzman SG 1984 Repeated administration of naltrexone and diprenorphine decreases food intake and body weight in squirrel monkeys. Life Sci 34:1-12 (Pubitemid 14215120)
28. Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, Goldman D 2008 An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the combined pharmacotherapies and behavioral interventions for alcohol dependence (COMBINE) study. Arch Gen Psychiatry 65:135-144 (Pubitemid 351222547)
29. Fontenelle LF, Oostermeijer S, Harrison BJ, Pantelis C, Yücel M 2011 Obsessive-compulsive disorder, impulse control disorders and drug addiction: common features and potential treatments. Drugs 71:827-840
30. Smith SG, Gupta KK, Smith SH 1995 Effects of naltrexone on selfinjury, stereotypy, and social behavior of adults with developmental disabilities. J Dev Phys Disabil 7:137-146
31. Grant JE, Kim SW, Odlaug BL 2009 A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania. Biol Psychiatr 65:600-606
32. Capasso R, Borrelli F, Cascio MG, Aviello G, Huben K, Zjawiony JK, Marini P, Romano B, Di Marzo V, Capasso F, Izzo AA 2008 Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitisinduced hypermotility: cross-talk between ≲καππα∀-opioid and cannabinoid CB(1) receptors. Br J Pharmacol 155:681-689
33. Pacheco Dda F, Klein A, Perez AC, Pacheco CM, De Francischi JN, Reis GM, Duarte ID 2009 Central antinociception induced by muopioid receptor agonist morphine, but not δ- or κ-, is mediated by cannabinoid CB1 receptor. Br J Pharmacol 158:225-231
34. Hojo M, Sudo Y, Ando Y, Minami K, Takada M, Matsubara T, Kanaide M, Taniyama K, Sumikawa K, Uezono Y 2008 mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci 108:308-319
35. Schoffelmeer AN, Hogenboom F, Wardeh G, De Vries TJ 2006 Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology 51:773-781 (Pubitemid 44308340)
36. Boustany-Kari CM, Jackson VM, Gibbons CP, Swick AG 2011 Leptin potentiates the anti-obesity effects of rimonabant. Eur J Pharmacol 658:270-276
37. Navarro HA, Howard JL, Pollard GT, Carroll FI 2009 Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter. Br J Pharmacol 156:1178-1184
38. Wu YK, Yeh CF, Ly TW, Hung MS 2011 A new perspective of cannabinoid 1 receptor antagonists: approaches toward peripheral CB1R blockers without crossing the blood-brain barrier. Curr Top Med Chem 11:1421-1429
39. Lazary J, Juhasz G, Hunyady L, Bagdy G 2011 Personalized medicine can pave the way for the safe use of CB1 receptor antagonists. Trends Pharmacol Sci 32:270-280
40. Martin B, Golden E, Keselman A, Stone M, Mattson MP, Egan JM, Maudsley S 2008 Therapeutic perspectives for the treatment ofHuntington's disease: treating the whole body. Histol Histopathol 23: 237-250
41. Maudsley S, Martin B, LuttrellLM2005 The origins of diversity and specificity in g protein-coupled receptor signaling. J Pharmacol Exp Ther 314:485-494 (Pubitemid 41043828)
42. Wang L, Martin B, Brenneman R, Luttrell LM, Maudsley S 2009 Allosteric modulators of g protein-coupled receptors: future therapeutics for complex physiological disorders. J Pharmacol Exp Ther 31:340-334